Medifast, Inc. (MED) Guidance & Earnings Results
On 2026-08-03 Medifast, Inc. lowered guidance: "Q3 revenue guidance $70-75M vs consensus…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MEDMedifast, Inc.Follow MED — free
—
Price chart with a free account
- Market cap
- 132.7M
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 26 Oct, in 2 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 3 Aug 26 | Lowered | Q3 revenue guidance $70-75M vs consensus ~$80M |
| 4 May 26 | Lowered | Q2 2026 revenue $60-80M; Q2 2026 loss per share $0.50-1.00; FY 2026 revenue $270-300M; FY 2026 loss per share $1.55-2.75 · full year |
| 3 Nov 25 | Lowered | Q4 2025 revenue $65M-$80M; Q4 2025 diluted loss per share $(0.70)-$(1.25) |
Medifast, Inc. — questions
- What guidance did Medifast, Inc. give?
- On 2026-08-03: "Q3 revenue guidance $70-75M vs consensus ~$80M"
- When does Medifast, Inc. report earnings?
- Medifast, Inc.'s next earnings report is expected on 2026-10-26.
Every figure on this page comes from Medifast, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.